JPWO2021187548A1 - - Google Patents
Info
- Publication number
- JPWO2021187548A1 JPWO2021187548A1 JP2022508425A JP2022508425A JPWO2021187548A1 JP WO2021187548 A1 JPWO2021187548 A1 JP WO2021187548A1 JP 2022508425 A JP2022508425 A JP 2022508425A JP 2022508425 A JP2022508425 A JP 2022508425A JP WO2021187548 A1 JPWO2021187548 A1 JP WO2021187548A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026003199A JP2026050471A (ja) | 2020-03-19 | 2026-01-13 | 慢性心不全の治療又は予防方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020048798 | 2020-03-19 | ||
| PCT/JP2021/011003 WO2021187548A1 (ja) | 2020-03-19 | 2021-03-18 | 慢性心不全の治療又は予防方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026003199A Division JP2026050471A (ja) | 2020-03-19 | 2026-01-13 | 慢性心不全の治療又は予防方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021187548A1 true JPWO2021187548A1 (https=) | 2021-09-23 |
| JPWO2021187548A5 JPWO2021187548A5 (https=) | 2024-03-27 |
Family
ID=77770987
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508425A Pending JPWO2021187548A1 (https=) | 2020-03-19 | 2021-03-18 | |
| JP2026003199A Pending JP2026050471A (ja) | 2020-03-19 | 2026-01-13 | 慢性心不全の治療又は予防方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026003199A Pending JP2026050471A (ja) | 2020-03-19 | 2026-01-13 | 慢性心不全の治療又は予防方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230321044A1 (https=) |
| EP (1) | EP4122495A4 (https=) |
| JP (2) | JPWO2021187548A1 (https=) |
| KR (1) | KR20220156574A (https=) |
| CN (1) | CN115209919B (https=) |
| AU (1) | AU2021237149A1 (https=) |
| BR (1) | BR112022018396A2 (https=) |
| CA (1) | CA3175131A1 (https=) |
| MX (1) | MX2022011490A (https=) |
| WO (1) | WO2021187548A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020343585B2 (en) * | 2019-09-04 | 2026-02-05 | Shionogi & Co., Ltd. | Chronic kidney disease treatment or prevention method |
| MX2022002683A (es) * | 2019-09-04 | 2022-04-07 | Japan Tobacco Inc | Metodo terapeutico o profilactico para diabetes usando medicamentos combinados. |
| WO2023210634A1 (ja) * | 2022-04-28 | 2023-11-02 | 国立大学法人東海国立大学機構 | 拡張障害を伴う心不全の治療用医薬組成物 |
| WO2025249555A1 (en) * | 2024-05-31 | 2025-12-04 | Japan Tobacco Inc. | Method for treating or preventing hypertrophic cardiomyopathy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019151627A (ja) * | 2018-03-01 | 2019-09-12 | 日本たばこ産業株式会社 | メチルラクタム環化合物及びその医薬用途 |
| JP2019182852A (ja) * | 2018-04-04 | 2019-10-24 | 日本たばこ産業株式会社 | ヘテロアリールで置換されたピラゾール化合物及びその医薬用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200735880A (en) * | 2006-01-27 | 2007-10-01 | Sankyo Co | Medicinal compositions for preventing or treating heart failure |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| CN110066302B (zh) * | 2018-01-23 | 2022-12-27 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
| MX2022002683A (es) * | 2019-09-04 | 2022-04-07 | Japan Tobacco Inc | Metodo terapeutico o profilactico para diabetes usando medicamentos combinados. |
-
2021
- 2021-03-18 EP EP21772065.5A patent/EP4122495A4/en active Pending
- 2021-03-18 JP JP2022508425A patent/JPWO2021187548A1/ja active Pending
- 2021-03-18 WO PCT/JP2021/011003 patent/WO2021187548A1/ja not_active Ceased
- 2021-03-18 MX MX2022011490A patent/MX2022011490A/es unknown
- 2021-03-18 BR BR112022018396A patent/BR112022018396A2/pt not_active Application Discontinuation
- 2021-03-18 CA CA3175131A patent/CA3175131A1/en active Pending
- 2021-03-18 AU AU2021237149A patent/AU2021237149A1/en active Pending
- 2021-03-18 US US17/796,606 patent/US20230321044A1/en active Pending
- 2021-03-18 KR KR1020227035794A patent/KR20220156574A/ko active Pending
- 2021-03-18 CN CN202180021810.3A patent/CN115209919B/zh active Active
-
2026
- 2026-01-13 JP JP2026003199A patent/JP2026050471A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019151627A (ja) * | 2018-03-01 | 2019-09-12 | 日本たばこ産業株式会社 | メチルラクタム環化合物及びその医薬用途 |
| JP2019182852A (ja) * | 2018-04-04 | 2019-10-24 | 日本たばこ産業株式会社 | ヘテロアリールで置換されたピラゾール化合物及びその医薬用途 |
Non-Patent Citations (3)
| Title |
|---|
| SAWA, YOHEI ET AL.: "Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 142, JPN6021013541, 7 November 2019 (2019-11-07), pages 16 - 25, ISSN: 0005552341 * |
| 弘瀬雅教 ほか: "心筋リモデリングとＮａ+／グルコース共輸送体タンパク１（ＳＧＬＴ１）", ＹＡＫＵＧＡＫＵ ＺＡＳＳＨＩ, vol. 138, no. 7, JPN6021013538, 2018, pages 939 - 943, ISSN: 0005552340 * |
| 弘瀬雅教: "心室性不整脈の発生におけるＳＧＬＴ１の活性化の関与", 科学研究費助成事業研究成果報告書, JPN6021013535, 2015, ISSN: 0005552339 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022018396A2 (pt) | 2022-11-08 |
| KR20220156574A (ko) | 2022-11-25 |
| EP4122495A1 (en) | 2023-01-25 |
| EP4122495A4 (en) | 2024-03-27 |
| CN115209919A (zh) | 2022-10-18 |
| CN115209919B (zh) | 2024-12-31 |
| WO2021187548A1 (ja) | 2021-09-23 |
| CA3175131A1 (en) | 2021-09-23 |
| MX2022011490A (es) | 2022-10-07 |
| US20230321044A1 (en) | 2023-10-12 |
| AU2021237149A1 (en) | 2022-10-06 |
| JP2026050471A (ja) | 2026-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025003792A1 (es) | Proceso para sintetizar derivados de naftiridina y sus compuestos intermedios. | |
| BR112023008622A2 (https=) | ||
| CN305680197S (https=) | ||
| CN305646485S (https=) | ||
| CN305550533S (https=) | ||
| CN305552946S (https=) | ||
| CN305556226S (https=) | ||
| CN305557124S (https=) | ||
| CN305557843S (https=) | ||
| CN305548727S (https=) | ||
| CN305561815S (https=) | ||
| CN305683525S (https=) | ||
| CN305681938S (https=) | ||
| CN305647260S (https=) | ||
| CN305648289S (https=) | ||
| CN305649552S (https=) | ||
| CN305650607S (https=) | ||
| CN305650817S (https=) | ||
| CN305654391S (https=) | ||
| CN305656086S (https=) | ||
| CN305657148S (https=) | ||
| CN305657305S (https=) | ||
| CN305671676S (https=) | ||
| CN306962662S (https=) | ||
| CN305549198S (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240315 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250318 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250716 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260113 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20260330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260330 |